Latest / MATCH B2B INSIGHTS / From Random to Repeatable: Why Medtech Pipeline Breaks in 2026

Transcript

From Random to Repeatable: Why Medtech Pipeline Breaks in 2026 · MATCH B2B INSIGHTS

• 0:26
  Welcome to MATCH B2B Insights.
• 0:29
  I'm בני פלומן, founder of MATCH B2B,
• 0:32
  and this show is really for Medtech CEOs and business development leaders
• 0:36
  who look up one day and realize,
• 0:38
  "We have good technology, we have some traction...
• 0:38
  so why does revenue still feel random?"And
• 0:45
  I'm Brian Newman.
• 0:46
  I work on the pipeline execution side of that problem.
• 0:48
  SDR architecture, outreach sequencing,
• 0:51
  buyer mapping, getting actual qualified conversations moving instead
• 0:55
  of just collecting names after an event and hoping something happens.
• 0:55
  Yeah.
• 1:00
  And today's topic is one we see again and again.
• 1:04
  A company has a solid product,
• 1:06
  maybe a few early customers, maybe even some impressive logos.
• 1:11
  On the surface it looks fine.
• 1:13
  The founders are busy, the sales deck is polished,
• 1:17
  conferences generate meetings,
• 1:19
  people say the market response is "encouraging." But underneath
• 1:25
  that, there is no real commercial engine.
• 1:25
  Right.
• 1:28
  It's momentum without a mechanism.
• 1:30
  That's the phrase I'd use.
• 1:31
  Because if you ask, "Where did the last five opportunities actually come from?"
• 1:35
  the answer is usually some mix of conference traffic,
• 1:38
  a distributor intro, an old founder contact,
• 1:41
  a referral from an advisor.
• 1:43
  Useful?
• 1:44
  Sure.
• 1:44
  Repeatable?
• 1:45
  Not really.
• 1:45
  Exactly.
• 1:47
  And that's the tension.
• 1:48
  What feels like growth is often just temporary access.
• 1:52
  It's not a system.
• 1:53
  It is a cluster of personal relationships and opportunistic moments.
• 1:57
  And the problem only becomes obvious when one of those channels slows
• 2:01
  down.
• 2:02
  Conference season ends.
• 2:04
  Referrals get thinner.
• 2:05
  The CEO gets pulled into fundraising,
• 2:08
  product, regulatory, operations...
• 2:10
  and suddenly the pipeline looks much weaker than everyone thought.
• 2:10
  And
• 2:14
  then people start trying to fix it tactically.
• 2:16
  "Let's send more emails." "Let's hire one salesperson." "Let's do more LinkedIn."
• 2:21
  But if the commercial motion underneath is weak,
• 2:24
  more activity just creates more noise.
• 2:26
  You end up with a calendar that looks busy and a CRM that looks active,
• 2:30
  but very little moves stage to stage.
• 2:30
  That's an important distinction.
• 2:34
  We are not talking about bad companies.
• 2:36
  Usually these are strong companies.
• 2:38
  The product team is capable.
• 2:39
  The clinical logic may be strong.
• 2:41
  The market need may be real.
• 2:43
  The issue is not product existence.
• 2:46
  The issue is commercial structure.
• 2:48
  Is there a defined journey from awareness to conversation to evaluation
• 2:53
  to internal buyer alignment to next step?
• 2:53
  And can somebody other than the
• 2:57
  CEO make that happen consistently?
• 2:59
  Because if every meaningful deal still depends on the founder stepping
• 3:02
  in with credibility, connections,
• 3:04
  and persistence, then the company doesn't yet have a commercial system.
• 3:08
  It has founder-assisted selling.
• 3:08
  Which is normal early on,
• 3:12
  by the way.
• 3:12
  I don't think founders should feel embarrassed by that.
• 3:15
  Early traction is often relationship-led.
• 3:18
  The mistake is assuming that because it worked at ten customers,
• 3:22
  it will scale to twenty, thirty,
• 3:24
  fifty.
• 3:24
  Usually it won't.
• 3:24
  Yeah, and especially in Medtech,
• 3:28
  people can confuse market interest with pipeline health.
• 3:31
  A booth was busy.
• 3:32
  The demo got good reactions.
• 3:34
  Somebody said, "Circle back in Q3." That is not revenue movement.
• 3:39
  That's just interest signal.
• 3:40
  It matters, but it is not enough.
• 3:40
  So that's where we're going today: how
• 3:44
  Medtech companies move from random to repeatable,
• 3:48
  and why what used to pass for commercial momentum is now much less reliable
• 3:53
  than it was a few years ago.
• 3:53
  Let's push this into current context,
• 3:58
  because this is more dangerous in 2026 than it was before.
• 4:02
  Healthcare buyers are under heavier pressure now.
• 4:06
  Budget scrutiny is tighter.
• 4:07
  Implementation risk is discussed earlier.
• 4:10
  And operational friction matters much more than many vendors want to
• 4:15
  admit.
• 4:15
  Yeah.
• 4:16
  A few years ago, some companies could get pretty far on innovation story
• 4:19
  alone.
• 4:20
  "Here's a better device." "Here's a smarter platform." "Here's a breakthrough
• 4:20
  capability."
• 4:25
  Now the buyer hears that and immediately starts translating it into work.
• 4:29
  Who has to approve this?
• 4:30
  Who has to change process?
• 4:32
  What's the training burden?
• 4:34
  What's the cost of rollout if this goes sideways?
• 4:34
  Exactly.
• 4:38
  The buying group is more cautious and more cross-functional.
• 4:42
  You are not just dealing with one champion who likes the technology.
• 4:46
  You're dealing with clinical stakeholders,
• 4:49
  operational stakeholders, procurement,
• 4:51
  sometimes finance, sometimes IT,
• 4:54
  depending on the solution.
• 4:55
  So if your message is still built mainly around product novelty,
• 5:01
  you are under-serving the decision process.
• 5:01
  And that creates a false read
• 5:06
  in early conversations.
• 5:07
  Teams say, "The demo went well." Fine.
• 5:10
  But did the demo answer the operational objections?
• 5:13
  Did it give the champion language they can reuse internally?
• 5:16
  Did it reduce perceived implementation complexity?
• 5:19
  If not, you're probably going to get a polite delay.
• 5:19
  I keep coming back
• 5:24
  to one thing: innovation is not the only risk the buyer sees.
• 5:28
  Sometimes it's not even the main one.
• 5:31
  The main risk is disruption.
• 5:34
  Will this interfere with workflow?
• 5:36
  Will staff resist it?
• 5:37
  Will the ROI take too long to prove?
• 5:40
  Will we spend internal political capital on something that does not scale
• 5:44
  inside the organization?
• 5:44
  And when Medtech companies keep selling the way
• 5:47
  they sold, let's say, even two or three years ago,
• 5:50
  they often lengthen their own cycle.
• 5:52
  They're leading with features,
• 5:54
  then more features, then another meeting to explain the features.
• 5:57
  Meanwhile the buyer is still unclear on adoption path.
• 6:00
  So the opportunity doesn't die dramatically.
• 6:03
  It just...
• 6:04
  drifts.Death by "let's revisit next quarter."Exactly.
• 6:11
  And because the company still has some top-of-funnel activity,
• 6:15
  they don't immediately diagnose the real problem.
• 6:17
  They think the market is slow.
• 6:19
  Sometimes the market is slow, sure.
• 6:21
  But often the bigger issue is that the company is creating uncertainty
• 6:24
  inside the buyer process.
• 6:24
  This is where the market has become unforgiving.
• 6:29
  Healthcare organizations are asking not only,
• 6:32
  "Is this clinically interesting?" but "Can we adopt this without creating extra
• 6:32
  drag?"
• 6:37
  and "Can you help us justify this in a measurable way?" If your commercial
• 6:42
  motion cannot answer those questions early,
• 6:45
  conversion weakens.
• 6:45
  And the smaller the company,
• 6:48
  the more dangerous that is.
• 6:49
  Because you don't have endless runway to absorb six-month delays caused
• 6:53
  by vague messaging and weak sequencing.
• 6:55
  You need fewer wasted conversations.
• 6:58
  You need clearer progression.
• 6:59
  You need a motion that earns attention and then guides it.
• 6:59
  Right.
• 7:03
  So the issue is not simply that buying is harder.
• 7:06
  The issue is that old selling habits are now more expensive.
• 7:11
  They produce longer cycles, lower confidence,
• 7:14
  and weaker conversion at exactly the stage where small Medtech companies
• 7:18
  can least afford it.
• 7:18
  So let's make that practical.
• 7:22
  What does the shift actually look like?
• 7:24
  For me, it's a move from an innovation story to an adoption story.
• 7:28
  Not because innovation stopped mattering.
• 7:31
  It absolutely matters.
• 7:32
  But novelty without implementation logic no longer creates enough urgency.
• 7:32
  Yeah,
• 7:39
  buyers need to see the path, not just the promise.
• 7:42
  A lot of companies still present like this: here's the technology,
• 7:46
  here's why it's unique, here's why it's better than legacy alternatives.
• 7:50
  And then they wonder why people nod in the meeting and disappear afterwards.
• 7:50
  Because
• 7:55
  the buyer is silently asking four questions that are often not being
• 7:55
  answered.
• 8:00
  One: who actually adopts this inside the organization?
• 8:03
  Two: how does workflow change?
• 8:07
  Three: where does friction appear in rollout?
• 8:11
  And four: what does ROI look like in the first six to twelve months?
• 8:11
  I'd
• 8:17
  add a fifth, maybe hidden question: "How much effort am I personally taking on if
• 8:17
  I sponsor this?"
• 8:23
  That's the political question.
• 8:24
  It's not always said out loud,
• 8:26
  but it's there.
• 8:27
  If your message increases that perceived effort,
• 8:30
  the deal slows down even if they like the product.
• 8:30
  That's a good point.
• 8:34
  Feature-led messaging tends to increase buyer uncertainty because it
• 8:38
  keeps the conversation centered on what the product is.
• 8:42
  Adoption-led messaging reduces uncertainty because it shows how the
• 8:42
  product
• 8:46
  becomes usable, supportable, and justifiable in a real care environment.
• 8:46
  So
• 8:52
  instead of saying, "We have these seven capabilities," you might say,
• 8:56
  "Here's where teams usually start, here's the workflow we do not ask you to change
• 8:56
  immediately, here's who needs to be involved early,
• 8:56
  and here's the operational metric customers care about first."
• 9:07
  That's a very different conversation.
• 9:07
  And a stronger one.
• 9:11
  Because now you're helping the buyer imagine safe adoption.
• 9:15
  In healthcare, that matters.
• 9:17
  Especially now, when implementation scrutiny is high and internal resources
• 9:21
  are stretched.
• 9:21
  Also, adoption-led messaging makes follow-up easier.
• 9:25
  If I send a note after a first meeting and all I say is,
• 9:28
  "Great to show you the platform, attached is our deck," that's weak.
• 9:32
  But if I can recap, "Based on your environment,
• 9:32
  the likely first-use case is X, the initial stakeholders are Y, and the
• 9:32
  main success metric in the first two quarters is Z,"
• 9:42
  now the conversation has shape.
• 9:42
  Yes.
• 9:45
  And shape creates momentum.
• 9:47
  This is why some companies with objectively good products still struggle
• 9:52
  commercially.
• 9:53
  They are over-explaining the solution and under-structuring the adoption
• 9:58
  path.
• 9:58
  I mean, bluntly, buyers don't buy novelty.
• 10:01
  They buy believable progress.
• 10:04
  Novelty may open the door.
• 10:05
  Believable progress is what gets internal support.
• 10:05
  That's well put.
• 10:09
  So if you're listening and thinking,
• 10:12
  "We keep getting interest but not commitment," look at your story.
• 10:15
  Are you selling technology superiority?
• 10:18
  Or are you helping the buyer see implementation,
• 10:21
  workflow fit, and measurable value inside a realistic timeframe?
• 10:21
  Because
• 10:26
  if it's mostly the first one, the market is probably hearing,
• 10:29
  "Interesting product." What you need them to hear is,
• 10:33
  "This can actually work hereLet's talk symptoms, because most teams feel the
• 10:33
  problem before they can name it.
• 10:33
  The obvious one is post-conference follow-up that stalls.
• 10:33
  You come back with a stack of conversations, maybe some badge scans,
• 10:33
  a few promising meetings, and then two weeks later almost nothing has
• 10:33
  progressed.
• 10:33
  And internally people say, "The
• 10:52
  event was good, but follow-up wasn't strong enough.
• 10:55
  " Sometimes that's true.
• 10:55
  But if this happens repeatedly, it's usually more than sloppy execution.
• 10:55
  It often means the company has no clear conversion path after initial interest.
• 10:55
  Another one: demos that don't convert.
• 10:55
  The team works hard to get the meeting.
• 10:55
  The meeting happens.
• 10:55
  Feedback sounds positive.
• 10:55
  Then silence, delay, or endless "we're
• 11:19
  still discussing internally.
• 11:20
  " Again, not always a product problem.
• 11:20
  Often it's that the demo answered curiosity, not commitment.
• 11:20
  Then there is the CEO-dependent pipeline.
• 11:20
  This one is huge.
• 11:20
  If the strongest opportunities all require the CEO to open the door,
• 11:20
  carry the credibility, rescue the follow-up,
• 11:20
  and push next steps, that's not just a heroic founder story.
• 11:20
  That's a structural dependency.
• 11:20
  Yeah.
• 11:20
  It means the market trusts the founder more than the commercial system.
• 11:20
  And that's a hard ceiling.
• 11:20
  Because the CEO cannot be the SDR, account executive, evangelist,
• 11:20
  and implementation strategist forever.
• 11:20
  Well, they can for a while, but it's not fun.
• 11:20
  And it distorts management perception.
• 11:20
  Because when the founder can still force some progress through personal effort,
• 11:20
  the organization underestimates how weak the underlying motion is.
• 11:20
  I see one more signal a lot: activity without progression.
• 11:20
  There are emails going out, LinkedIn messages happening,
• 11:20
  webinars maybe, meetings on the calendar.
• 11:20
  But if you inspect the stages, nothing moves with consistency.
• 11:20
  That's usually structural, not tactical.
• 11:20
  Weak ICP focus, unclear sequencing, inconsistent follow-up, and message drift
• 11:20
  all combine to create the illusion of traction.
• 11:20
  Exactly.
• 11:20
  Volume can hide design flaws.
• 11:20
  You can be very busy and commercially incoherent at the same time.
• 11:20
  If the ideal customer profile is too broad, your outreach will be diluted.
• 11:20
  If you haven't mapped the buying committee, you will speak to the wrong
• 11:20
  person too long.
• 11:20
  If your follow-up does not guide a next decision, you will create pleasant
• 11:20
  conversations that go nowhere.
• 11:20
  And poor follow-up isn't just "forgot
• 13:02
  to send an email.
• 13:02
  " It's also sending the wrong kind of follow-up.
• 13:02
  Generic recap.
• 13:02
  Deck attachment.
• 13:02
  "Just
• 13:08
  checking in.
• 13:09
  " Those do not move a cautious healthcare buyer forward.
• 13:09
  So when people ask, "Is
• 13:14
  this a market problem or an execution problem?
• 13:16
  " my answer is often: neither, exactly.
• 13:16
  It is an architecture problem.
• 13:16
  The company lacks a structured path from signal to qualified opportunity.
• 13:16
  And once you frame it that way, the fix changes.
• 13:16
  You stop chasing random tactics and start asking better questions.
• 13:16
  Who are we really for?
• 13:16
  What triggers urgency?
• 13:16
  Which stakeholder needs what message?
• 13:16
  What should happen after a first conversation?
• 13:16
  That's where repeatability begins.
• 13:16
  One reason we're speaking pretty directly about this is that MATCH B2B is currently
• 13:16
  in dialogue with multiple Medtech companies in the U.
• 13:16
  S.
• 13:16
  Those are live conversations, active commercial discussions, and
• 13:16
  they're sharpening our view of buyer expectations in real time.
• 13:16
  Yeah, and what's interesting is the pattern is consistent even across
• 13:16
  different categories.
• 13:16
  The internal story inside the company is often, "Our
• 14:09
  value is obvious.
• 14:10
  " But when you unpack what buyers are actually responding to, there is a gap.
• 14:10
  Sometimes a big one.
• 14:10
  The internal narrative tends to be capability-heavy.
• 14:10
  Sophisticated technology, differentiated functionality,
• 14:10
  strong clinical rationale.
• 14:10
  All good.
• 14:10
  But buyers are filtering through a different lens.
• 14:10
  They want to understand adoption risk, workflow fit, and ROI justification much
• 14:10
  earlier than many teams expect.
• 14:10
  And they don't always say it directly.
• 14:10
  That's the tricky part.
• 14:10
  A buyer may be polite, engaged, even enthusiastic.
• 14:10
  But if you're not hearing strong movement, it's often because they still
• 14:10
  don't know how this lands operationally.
• 14:10
  They're asking themselves, "Does
• 14:50
  this add friction to staff?
• 14:52
  Do we need cross-department coordination?
• 14:54
  Can we show a payoff in a timeframe leadership will accept?
• 14:57
  "Exactly.
• 14:57
  Another thing we're hearing is that value narratives built for investors or
• 14:57
  industry visibility do not automatically convert in enterprise healthcare
• 14:57
  conversations.
• 14:57
  A company can sound impressive and still be commercially unclear.
• 14:57
  That's a big one.
• 14:57
  The story that works on a stage or in a thought leadership piece isn't always the
• 14:57
  story that gets a director, operator, or buying group to take the next step.
• 14:57
  The market wants specificity.
• 14:57
  Where do we start?
• 14:57
  What's the lowest-friction entry point?
• 14:57
  What changes first?
• 14:57
  What evidence matters?
• 14:57
  And in these U.
• 14:57
  S.
• 14:57
  conversations, the pressure around implementation is very tangible.
• 14:57
  Buyers are not just choosing between solutions.
• 14:57
  They are choosing between levels of disruption.
• 14:57
  If your message doesn't reduce perceived disruption, you are making the commercial
• 14:57
  job harder than it needs to be.
• 14:57
  I also think buyer patience for vague ROI has dropped.
• 14:57
  "Long-term
• 15:57
  transformation" is not enough on its own.
• 15:57
  They want a credible near-term logic.
• 15:57
  Not fantasy numbers, not inflated savings claims, but a
• 15:57
  realistic line of sight to operational value.
• 15:57
  That's important: credible, not theatrical.
• 15:57
  A lot of commercial language in Medtech still overreaches.
• 15:57
  But the buyers we're seeing respond better when the company is disciplined,
• 15:57
  specific, and honest about how value accumulates.
• 15:57
  So these live market signals are useful because they move us beyond theory.
• 15:57
  This isn't us guessing from a distance.
• 15:57
  We're hearing directly where companies are getting stuck and what buyers need to
• 15:57
  feel confident enough to progress.
• 15:57
  And the message is quite clear: strong innovation is still necessary,
• 15:57
  but it is not sufficient.
• 15:57
  The commercial winners will be the companies that translate innovation into
• 15:57
  adoptable, low-friction, financially understandable progress.
• 15:57
  So if random effort isn't the answer, what does a repeatable system actually
• 15:57
  require?
• 15:57
  For me it starts with clarity.
• 15:57
  Clear ICP first.
• 15:57
  Not "hospitals" as a category.
• 15:57
  That's not an ICP.
• 15:57
  You need to know what kind of organization, what context,
• 15:57
  what pain pattern, what maturity, what likely entry point.
• 15:57
  Yes.
• 15:57
  If the target is vague, the message becomes vague,
• 15:57
  the outreach becomes vague, and the pipeline becomes noisy.
• 15:57
  After ICP, the next layer is buying committee mapping.
• 15:57
  Who can initiate?
• 15:57
  Who can block?
• 15:57
  Who cares about workflow?
• 15:57
  Who cares about budget logic?
• 15:57
  Who needs evidence in what form?
• 15:57
  Then message discipline.
• 15:57
  That's a practical thing, not a branding slogan.
• 15:57
  It means your outreach, your first call, your deck, your follow-up,
• 15:57
  your LinkedIn posts, even webinar themes, all reinforce the same commercial logic.
• 15:57
  Not one story for marketing, another for sales,
• 15:57
  another for the CEO in investor mode.
• 15:57
  And then stage-based customer journey design.
• 15:57
  This is where smaller companies often get relief.
• 15:57
  They think scale requires a big team.
• 15:57
  It doesn't necessarily.
• 15:57
  What it requires is a defined journey.
• 15:57
  What should a prospect understand after first contact?
• 15:57
  What should happen after a discovery conversation?
• 15:57
  What evidence is needed before a pilot discussion?
• 15:57
  What internal concerns need to be addressed before procurement friction
• 15:57
  appears?
• 15:57
  Exactly.
• 15:57
  When that's designed well, a small Medtech team can cover hospitals,
• 15:57
  clinics, and distributors far more efficiently.
• 15:57
  Not by doing more random outreach, but by using a tailored sequence for each route
• 15:57
  to market.
• 15:57
  Different stakeholders, different objections, different pacing,
• 15:57
  but one coherent architecture underneath.
• 15:57
  And this is the part I want to stress: repeatability is not hustle.
• 15:57
  It is not "everyone
• 18:43
  work harder after the conference.
• 18:44
  " Repeatability comes from commercial architecture.
• 18:44
  It comes from deciding how demand is created, how trust is built,
• 18:44
  how qualification happens, how handoffs work,
• 18:44
  and how next steps are defined.
• 18:44
  You also need operational discipline.
• 18:44
  Simple KPIs, but meaningful ones.
• 18:44
  Not vanity metrics.
• 18:44
  I don't care if you sent 800 emails if none reached the right stakeholders with
• 18:44
  the right message.
• 18:44
  I care whether conversations progressed with accounts that fit the ICP and
• 18:44
  whether follow-up created movement.
• 18:44
  That's where strategy and execution have to meet.
• 18:44
  Because a good system is not abstract.
• 18:44
  It should reduce commercial drag.
• 18:44
  It should make forecasting less emotional.
• 18:44
  And it should allow the business to grow without adding headcount every time you
• 18:44
  want more pipeline.
• 18:44
  And that's especially important for companies in the ten-to-fifty-person
• 18:44
  range.
• 18:44
  Resources are tight.
• 18:44
  You don't want operational drag.
• 18:44
  You want a lean motion that can be refined, measured, and improved.
• 18:44
  That's how you go from occasional wins to a pipeline you can actually work with.
• 18:44
  Let's talk content, because this gets misunderstood a lot.
• 18:44
  Thought leadership is not valuable because it makes you look active.
• 18:44
  It is valuable if it creates trust with a precise buyer and moves that buyer toward
• 18:44
  a structured next step.
• 18:44
  Yeah.
• 18:44
  Visibility alone is a weak outcome.
• 18:44
  I mean, it's nice.
• 18:44
  But if the content does not help a target buyer say, "These
• 20:14
  people understand the problem I'm actually dealing with," then it's just
• 20:14
  market noise.
• 20:14
  And in Medtech, the strongest content is usually problem-based,
• 20:14
  not self-celebratory.
• 20:14
  Start from the commercial reality the buyer is living.
• 20:14
  Post-conference follow-up that goes nowhere.
• 20:14
  Innovation interest without adoption clarity.
• 20:14
  Internal resistance because workflow impact is vague.
• 20:14
  Those are conversation starters.
• 20:14
  Then add evidence and business-outcome framing.
• 20:14
  Not just, "Our
• 20:46
  platform is advanced," but "Here's where commercial friction typically
• 20:49
  appears, here's how smart teams reduce it,
• 20:52
  here's what buyers want to understand before they move.
• 20:55
  " That kind of content earns a different level of attention.
• 20:55
  Exactly.
• 20:55
  Because now the company is acting like a credible guide,
• 20:55
  not just a vendor asking for a meeting.
• 20:55
  And from there, content has to connect into a conversion path.
• 20:55
  LinkedIn, webinars, outreach, and follow-up should not be disconnected
• 20:55
  tactics.
• 20:55
  Right.
• 20:55
  If someone engages with a post, attends a webinar, downloads something,
• 20:55
  or replies to outreach, the next step should feel natural.
• 20:55
  Not, "Book
• 21:24
  a demo" immediately.
• 21:24
  Maybe it's a focused discussion around a specific commercial problem.
• 21:24
  Maybe it's a short diagnostic.
• 21:24
  But there has to be a bridgeThis is why content strategy and pipeline strategy
• 21:24
  cannot live in separate rooms.
• 21:24
  If marketing is publishing broad thought leadership and sales is sending generic
• 21:24
  outbound, you break the buyer experience.
• 21:24
  Trust is created in one place and then wasted in another.
• 21:24
  And consistency matters.
• 21:24
  One good webinar won't fix weak architecture.
• 21:24
  But if your messaging is disciplined, content can pre-educate the market.
• 21:24
  It can warm up the exact objections that otherwise slow down calls.
• 21:24
  It can make outreach feel familiar rather than intrusive.
• 21:24
  I sometimes say content should do three jobs: sharpen positioning,
• 21:24
  reduce buyer uncertainty, and create entry into a real conversation.
• 21:24
  If it's not doing at least two of those, it's probably not helping enough.
• 21:24
  That's good.
• 21:24
  And the outreach side gets easier when content is aligned.
• 21:24
  SDR or founder follow-up can reference a clear commercial point the market has
• 21:24
  already seen.
• 21:24
  That makes the conversation less about, "Can
• 22:29
  we get 30 minutes?
• 22:30
  " and more about, "You mentioned this problem - are you seeing the same
• 22:34
  thing internally?
• 22:35
  " Much stronger.
• 22:35
  So the goal is not content for content's sake.
• 22:35
  The goal is one integrated path from message to trust to conversation to
• 22:35
  opportunity.
• 22:35
  That's when thought leadership starts behaving like revenue infrastructure
• 22:35
  instead of marketing activity.
• 22:35
  Maybe this is a good place to explain why Brian and I approach this together,
• 22:35
  because the split matters.
• 22:35
  My role is usually to diagnose the growth constraint.
• 22:35
  Where is the commercial model misaligned?
• 22:35
  Is the value proposition aimed at the wrong maturity level?
• 22:35
  Is demand generation disconnected from sales reality?
• 22:35
  Is pricing logic, message logic, and buyer expectation misaligned?
• 22:35
  And my side is translating that into motion.
• 22:35
  OK, if the ICP is this, who are the actual people inside the account?
• 22:35
  What sequence do we use?
• 22:35
  What message lands first?
• 22:35
  What does follow-up look like?
• 22:35
  How do we turn a strategy deck into meetings with the right stakeholders and
• 22:35
  real pipeline progression?
• 22:35
  Exactly.
• 22:35
  Because many companies are not missing effort.
• 22:35
  They are missing alignment.
• 22:35
  They may have content, outreach, founder involvement, even some inbound.
• 22:35
  But the pieces don't reinforce each other.
• 22:35
  The result is scattered activity.
• 22:35
  And scattered activity usually creates random wins, which can be misleading.
• 22:35
  You close one deal and think, "Great,
• 23:55
  let's just do more of that.
• 23:56
  " But if you can't explain why it worked and repeat it outside the founder's
• 23:56
  network, you're not building a system.
• 23:56
  This is where the strategic and operational combination matters.
• 23:56
  Strategy without execution stays theoretical.
• 23:56
  Execution without strategy becomes busywork.
• 23:56
  What companies need is a commercial architecture that is then made executable
• 23:56
  in the market.
• 23:56
  Yeah, and honestly, the operational piece has to be grounded in reality.
• 23:56
  Small Medtech teams can't afford bloated sales structures.
• 23:56
  They need lean systems.
• 23:56
  Tight messaging.
• 23:56
  Good research.
• 23:56
  Clear prioritization.
• 23:56
  Smart follow-up.
• 23:56
  Relentless iteration.
• 23:56
  That's how you create qualified conversations in weeks,
• 23:56
  not months of internal debate.
• 23:56
  And the diagnosis has to be honest.
• 23:56
  Sometimes the issue is not outreach volume.
• 23:56
  Sometimes the issue is that the company is talking about itself in a way the
• 23:56
  buyer cannot use.
• 23:56
  Sometimes the route to market is muddled.
• 23:56
  Sometimes the customer journey has gaps.
• 23:56
  Unless you identify the true bottleneck, you will optimize the wrong thing.
• 23:56
  I think that's why these engagements work best when founders are willing to hear,
• 23:56
  "You
• 25:09
  don't have a lead problem.
• 25:11
  You have a progression problem," or "You don't have a messaging problem
• 25:14
  alone.
• 25:15
  You have a sequencing problem.
• 25:16
  " It's not always the headline issue they expected.
• 25:16
  Yes.
• 25:16
  But once the issue is named correctly, progress becomes much more practical.
• 25:16
  You can rebuild the journey, tighten the narrative, define the stages,
• 25:16
  and create a measurable pipeline motion.
• 25:16
  That's the move from scattered effort to predictable commercial behavior.
• 25:16
  And that's really what this whole conversation is about.
• 25:16
  Not more noise.
• 25:16
  More structure that actually produces measurable pipeline.
• 25:16
  So let's close this in a practical way.
• 25:16
  If parts of this episode felt uncomfortably familiar, the first step is
• 25:16
  not a giant transformation project.
• 25:16
  Usually it's a diagnostic conversation.
• 25:16
  Brian, when someone speaks with you first,
• 25:16
  what should they expect?
• 25:16
  A practical conversation, basically.
• 25:16
  We're looking at where the pipeline is breaking today.
• 25:16
  Is the real problem ICP definition?
• 25:16
  Is it messaging that creates interest but not urgency?
• 25:16
  Is it sequencing?
• 25:16
  Is follow-up too weak?
• 25:16
  Is the CEO carrying too much of the commercial load?
• 25:16
  I'm trying to identify the actual source of friction,
• 25:16
  not just the symptom that hurts the most.
• 25:16
  And that's important, because companies often come in saying,
• 25:16
  "We
• 26:27
  need more leads," when the deeper issue is conversion design.
• 26:27
  Exactly.
• 26:27
  So the conversation usually gets pretty concrete.
• 26:27
  What does your pipeline currently depend on?
• 26:27
  What happens after conferences?
• 26:27
  What happens after demos?
• 26:27
  Which stakeholders are you speaking to?
• 26:27
  What are they responding to?
• 26:27
  Where are deals stalling?
• 26:27
  Once we see that, we can outline an initial process - what to tighten first,
• 26:27
  what to stop doing, and what realistic next steps might look like.
• 26:27
  And expectation setting matters too.
• 26:27
  Not fantasy promises.
• 26:27
  Realistic ROI logic.
• 26:27
  If the company changes its commercial architecture,
• 26:27
  what kind of improvement is plausible?
• 26:27
  Over what timeline?
• 26:27
  Under what level of internal commitment?
• 26:27
  Yeah, I never want these conversations to feel vague or over-sold.
• 26:27
  Sometimes the answer is, "You
• 27:16
  need clearer messaging and better follow-up.
• 27:18
  " Sometimes it's broader: ICP, journey, outreach structure, content alignment.
• 27:18
  But the goal is clarity.
• 27:18
  What is broken, what would a fix involve, and what outcomes are realistic from
• 27:18
  there?
• 27:18
  So if you're a Medtech CEO or business development leader in that
• 27:18
  ten-to-fifty-person range, and you're seeing the signals we discussed -
• 27:18
  post-conference follow-up stalling, demos not converting,
• 27:18
  CEO-dependent pipeline, lots of activity but little progression - it may be worth
• 27:18
  having that conversation.
• 27:18
  You can reach me directly at brian.
• 27:18
  newman@match-b2b.
• 27:18
  com, or by phone at +972549990168.
• 27:18
  And WhatsApp is absolutely welcome.
• 27:18
  If the situation feels familiar, send a note, give me a call, and we can
• 27:18
  talk through the pipeline gaps, what a process could look like, and what
• 27:18
  kind of ROI is actually realistic.
• 27:18
  That's the right tone for it - helpful, direct, no theater.
• 27:18
  And really that's the spirit of this podcast.
• 27:18
  We're not here to admire the problem.
• 27:18
  We're here to name it clearly and move toward a better commercial system.
• 27:18
  Yeah.
• 27:18
  If this episode got you asking some hard questions internally, good.
• 27:18
  That's probably useful.Brian, thanks.
• 27:18
  Good conversation.
• 27:18
  Thanks, Benny.
• 27:18
  Appreciate it.
• 27:18
  And to everyone listening, we'll keep going deeper on the structural issues
• 27:18
  behind Medtech growth.
• 27:18
  See you next time.
• 27:18
  Bye, everyone.